Maria Fardis

Form D signer

Maria Fardis

Chief Executive Officer at AirNexis Therapeutics

Form D signer

Capital raised by AirNexis Therapeutics

$62.0M+$62.0M latest round

1 Form D filing · first filed Jan 2026 · Palo Alto, CA

CURRENT ROLE: Chief Executive Officer
SECTOR: Biotech
COMPANY FILINGS: 1
TEAM ON FILE: 2
FOUNDED: 2024
30D INTEREST: 1 ↗

Career

1 company on file · founded 2024

AirNexis TherapeuticsBiotech · Palo Alto, CAsince 2024

Chief Executive Officer

Signatory on AirNexis Therapeutics's Form D filings · $62.0M raised across 1

Company filings

via EDGAR · Form D for AirNexis Therapeutics1

DateCompanyFormAmountRole on filing

Jan 9, 2026AirNexis TherapeuticsForm D+$62.0MChief Executive Officer

Form DJan 9, 2026 · AirNexis Therapeutics+$62.0Mas Chief Executive Officer

Overview

Last filing Jan 9, 2026

Maria Fardis is on file as Chief Executive Officer at AirNexis Therapeutics in Palo Alto, CA. AirNexis Therapeutics has 1 Form D filing on record, $62.0M raised in total. Maria Fardis appears as a signatory on the company's filings.

Teammates

AirNexis Therapeutics · 1

James LiDirector

Products

AirNexis Therapeutics · 1

AN01 (HSK39004)COPD Therapeutic

AN01 is an inhaled, dual-mechanism phosphodiesterase 3 and 4 (PDE3/4) inhibitor in Phase 2 development. It is intended for the maintenance treatment of COPD. The company holds exclusive global development rights outside of Greater China, having licensed the asset from Haisco Pharmaceutical Group, which previously advanced it through Phase 2 trials in China.